Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.54 |
| ▸ | PIM1 | P11309 | 6/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960062 | 0.87 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL7978467 | 0.87 | MEN1 (0.50) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6996160 | 0.84 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6768850 | 0.83 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6998699 | 0.81 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6993389 | 0.81 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL7192432 | 0.80 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL2646048 | 0.78 | RXFP1 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6994194 | 0.77 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL9690970 | 0.76 | BRD4 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109104-A1 | BIVALENT INHIBITORS OF AKT PROTEIN KINASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109104-A1 | BIVALENT INHIBITORS OF AKT PROTEIN KINASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-12 | — | — | WO | disclosed |
| US-7098208-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-20060030564-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2006-02-09 | — | — | US | disclosed |
| US-6958334-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1496981-A2 | METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040122012-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2004-06-24 | — | — | US | disclosed |
| US-20040116433-A1 | Triazolo[4,3b]pyridazine to inhibit activity of serine/threonine protein kinases tor treatment of cancer with administering | OWENS ANDREW PATE (GB) | 2004-06-17 | — | — | US | disclosed |
| US-20040106540-A1 | Method of treating cancer | BARNETT STANLEY F (US) | 2004-06-03 | — | — | US | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-1049697-B1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002083139-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083140-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6355798-B1 | LIGANDS FOR GAMMA-AMINOBUTYRIC ACID RECEPTORS; ANTICONVULSANTS, ANXIOLYTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-03-12 | — | — | US | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| EP-1049697-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037645-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142178-A1 | Method of treating cancer | PACSIN2, CTTN, TNK2 | GABRA1 4046/4885GABRG2 3417/4885GABRB3 2919/4885 |
| US-20060030564-A1 | Inhibitors of Akt activity | AKT2, AKT1, PLK1 | GABRA1 4623/4885GABRG2 4432/4885GABRB3 4439/4885 |
| US-20040122012-A1 | Inhibitors of akt activity | PIK3CD, AKT2, PIK3CA | GABRA1 3397/4885GABRG2 3472/4885GABRB3 3248/4885 |
| US-20040106540-A1 | Method of treating cancer | PACSIN2, CTTN, PLK1 | GABRA1 4046/4885GABRG2 3403/4885GABRB3 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.